ASH 2022 | The potential role of belantamab mafodotin in multiple myeloma
In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, comments on the potential role of belantamab mafodotin for the treatment of multiple myeloma. Although this agent was recently withdrawn from the US market, Dr Lesokhin explains that this highly effective antibody-drug conjugate (ADC) may still be a valuable option for patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer, Genmab, Sanofi, Iteos, BMS, Janssen: Consultancy; Memorial Sloan Kettering Cancer Center: Current Employment; Janssen, Pfizer, BMS, Genentech/Roche: Research Funding; Janssen, Pfizer, Iteos, Sanofi, Genmab: Honoraria; Serametrix, inc: Patents & Royalties; Trillium Therapeutics: Consultancy, Research Funding; Sanofi: Research Funding; BMS: Honoraria; Amgen: Honoraria.
